These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 30060063

  • 1. Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations.
    Hallén J, Sreeharan N.
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct 01; 4(4):237-242. PubMed ID: 30060063
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Drugs for hypertriglyceridemia.
    Med Lett Drugs Ther; 2013 Mar 04; 55(1411):17-9. PubMed ID: 23467119
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.
    Kohan AB.
    Curr Opin Endocrinol Diabetes Obes; 2015 Apr 04; 22(2):119-25. PubMed ID: 25692924
    [Abstract] [Full Text] [Related]

  • 8. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text.
    Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG.
    Curr Vasc Pharmacol; 2019 Apr 04; 17(5):498-514. PubMed ID: 31060488
    [Abstract] [Full Text] [Related]

  • 9. Hypertriglyceridemia, an Underestimated Cardiovascular Risk Factor: An Epidemiological Study of the Rome Area.
    Volpe R, Nati G, Chiriatti A, Sabatini M, Valente F, Gruppo Progetto DATAMeg.
    High Blood Press Cardiovasc Prev; 2017 Dec 04; 24(4):401-404. PubMed ID: 28710676
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review.
    Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG.
    Curr Vasc Pharmacol; 2019 Dec 04; 17(5):515-537. PubMed ID: 31309820
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement.
    Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG.
    Curr Vasc Pharmacol; 2019 Dec 04; 17(5):538-540. PubMed ID: 31418346
    [No Abstract] [Full Text] [Related]

  • 15. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.
    Nordestgaard BG.
    Circ Res; 2016 Feb 19; 118(4):547-63. PubMed ID: 26892957
    [Abstract] [Full Text] [Related]

  • 16. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
    Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, Shlomo N, Israel A, Tenenbaum A.
    Circ Cardiovasc Qual Outcomes; 2016 Mar 19; 9(2):100-8. PubMed ID: 26957517
    [Abstract] [Full Text] [Related]

  • 17. A New Beginning for Triglyceride-Lowering Therapies.
    Pradhan AD.
    Circulation; 2019 Jul 16; 140(3):167-169. PubMed ID: 30836784
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The role of triglycerides in cardiovascular risk.
    Gandotra P, Miller M.
    Curr Cardiol Rep; 2008 Nov 16; 10(6):505-11. PubMed ID: 18950562
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.
    Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, K-877 Study Group.
    Atherosclerosis; 2017 Jun 16; 261():144-152. PubMed ID: 28410749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.